Zhao L - Search Results

1

Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension.

Chen CN, Watson G, Zhao L. Chen CN, et al. Among authors: zhao l. Vascul Pharmacol. 2013 Mar;58(3):211-8. doi: 10.1016/j.vph.2012.09.001. Epub 2012 Sep 12. Vascul Pharmacol. 2013. PMID: 22982057 Review.

2

Sildenafil inhibits hypoxia-induced pulmonary hypertension.

Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR. Zhao L, et al. Circulation. 2001 Jul 24;104(4):424-8. doi: 10.1161/hc2901.093117. Circulation. 2001. PMID: 11468204 Clinical Trial.

3

Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity.

Zhao L, Mason NA, Strange JW, Walker H, Wilkins MR. Zhao L, et al. Circulation. 2003 Jan 21;107(2):234-7. doi: 10.1161/01.cir.0000050653.10758.6b. Circulation. 2003. PMID: 12538421

4

Simvastatin and sildenafil combine to attenuate pulmonary hypertension.

Zhao L, Sebkhi A, Ali O, Wojciak-Stothard B, Mamanova L, Yang Q, Wharton J, Wilkins MR. Zhao L, et al. Eur Respir J. 2009 Oct;34(4):948-57. doi: 10.1183/09031936.00143508. Eur Respir J. 2009. PMID: 19797670 Free article.

5

[Future treatment of pulmonary arterial hypertension].

Wilkins MR, Zhao L. Wilkins MR, et al. Among authors: zhao l. Zhonghua Yi Xue Za Zhi. 2009 Aug 11;89(30):2097-8. Zhonghua Yi Xue Za Zhi. 2009. PMID: 20058610 Chinese. No abstract available.

6

Atorvastatin in pulmonary arterial hypertension (APATH) study.

Zeng WJ, Xiong CM, Zhao L, Shan GL, Liu ZH, Xue F, Gu Q, Ni XH, Zhao ZH, Cheng XS, Wilkins MR, He JG; Atorvastatin in Pulmonary Arterial Hypertension (APATH) Study Group. Zeng WJ, et al. Among authors: zhao zh, zhao l. Eur Respir J. 2012 Jul;40(1):67-74. doi: 10.1183/09031936.00149011. Epub 2012 Feb 23. Eur Respir J. 2012. PMID: 22362846 Free article. Clinical Trial.

7

BMPR-II deficiency elicits pro-proliferative and anti-apoptotic responses through the activation of TGFβ-TAK1-MAPK pathways in PAH.

Nasim MT, Ogo T, Chowdhury HM, Zhao L, Chen CN, Rhodes C, Trembath RC. Nasim MT, et al. Among authors: zhao l. Hum Mol Genet. 2012 Jun 1;21(11):2548-58. doi: 10.1093/hmg/dds073. Epub 2012 Mar 2. Hum Mol Genet. 2012. PMID: 22388934

8

Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.

Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wang D, Li M, McKinsey TA, Stenmark KR, Wilkins MR. Zhao L, et al. Circulation. 2012 Jul 24;126(4):455-67. doi: 10.1161/CIRCULATIONAHA.112.103176. Epub 2012 Jun 18. Circulation. 2012. PMID: 22711276 Free PMC article.

9

Response to letter regarding article, “histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid”.

Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wilkins MR, Wang D, Li M, Stenmark KR, McKinsey TA, Buttrick P. Zhao L, et al. Circulation. 2013 Apr 9;127(14):e540. doi: 10.1161/circulationaha.112.154757. Circulation. 2013. PMID: 23691553 No abstract available.

10

Pulmonary hypertension: old targets revisited (statins, PPARs, beta-blockers).

Watson G, Oliver E, Zhao L, Wilkins MR. Watson G, et al. Among authors: zhao l. Handb Exp Pharmacol. 2013;218:531-48. doi: 10.1007/978-3-642-38664-0_21. Handb Exp Pharmacol. 2013. PMID: 24092354 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

34,637 results

Search Page